




ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Bologna

Policlinico S. Orsola-Malpighi

International Symposium on: URIC ACID CARDIOVASCULAR DISEASE: BACK TO PATHOPHYSIOLOGY

Bologna (Italy), December 1st - 3rd, 2016

Organized by

DEPARTMENT OF MEDICAL AND SURGICAL SCIENCES (DIMEC)
ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA
BOLOGNA, ITALY

DIVISION OF RENAL DISEASES AND HYPERTENSION
UNIVERSITY OF COLORADO
ANSCHUTZ MEDICAL CAMPUS – DENVER CO, USA

Promoted by



FONDAZIONE
INTERNAZIONALE
MENARINI

PROGRAM

Palazzo Re Enzo (Piazza del Nettuno, 1)

=====
The role of serum uric acid as a risk factor for CV disease has been extensively debated for many years without reaching a final agreement among clinicians and researchers. In particular, most of the evidence about the pathogenetic role of uric acid in CV disease have been achieved in the population of patients with severe hyperuricemia or gout while its role in patients with mildly elevated serum levels of uric acid is only poorly recognized. Serum uric acid represents an important, independent risk factor for cardiovascular and renal disease in patients with hypertension, heart failure, or diabetes. Elevated serum uric acid is highly predictive of mortality in patients with heart failure or coronary artery disease and of cardiovascular events in patients with diabetes. Although the mechanism(s) by which uric acid may play a pathogenetic role in cardiovascular disease is still unclear, hyperuricemia is associated with deleterious effects on endothelial dysfunction, oxidative metabolism, platelet adhesiveness, hemrheology, and aggregation. Whether a reduction in uric acid impacts CV and renal disease remains to be determined. However, recent findings from LIFE suggest the possibility that a treatment-induced decrease in serum uric acid may indeed attenuate cardiovascular risk. Clearly, randomized clinical trials are needed to investigate further the long-term cardioprotective benefits issue of reducing hyperuricemia in hypertensive patients..

The main purpose of the present symposium is twofold. First of all to reinforce the role of uric acid in the pathogenesis of gout and gout-related non-rheumatic diseases including renal involvement. Second to provide an updated review of the evidence supporting a possible and relevant role of (elevated) uric acid as a risk factor for cardiovascular diseases. To fullfil this goal we will present a series of comprehensive lectures mainly focused on the different aspects of the relationship between serum uric acid and cardiovascular diseases with the aim to define whether or not the increase in the amount of our knowledge about uric acid may contribute to increase the number of major risk factors.

Presidents of the Meeting
Claudio Borghi and Richard J. Johnson

=====

With the Patronage of

Health Office Emilia Romagna Region
Assessorato alle Politiche per la Salute Regione Emilia Romagna

Major of the City of Bologna

University Hospital of Bologna Policlinico S. Orsola Malpighi

Department of Medical and Surgical Sciences (DIMEC)
Alma Mater Studiorum University of Bologna

European Society of Hypertension

Italian Society of Hypertension

Presidents of the Meeting

Claudio Borghi

Department of Medical and Surgical Sciences (DIMEC)
Alma Mater Studiorum University of Bologna
Bologna, Italy

Richard J. Johnson

Division of Renal Diseases and Hypertension
University of Colorado
Anschutz Medical Campus
Denver, CO - USA

Scientific Secretariat

Stefania Corvaglia

University Hospital of Bologna
Policlinico S. Orsola - Malpighi, Bologna, Italy

Arrigo F.G. Cicero

Alma Mater Studiorum Università di Bologna
Bologna, Italy

Promoted by

Fondazione Internazionale Menarini

Edificio L - Strada 6
Centro Direzionale Milanofiori
I-20089 Rozzano (Milan, Italy)
Phone: +39 02 55308110 - Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
Http:\\www.fondazione-menarini.it

Organizing Secretariat and Provider for Italian CME accreditation

I&C s.r.l.

Via Andrea Costa, 202/6
I-40134 Bologna (Italy)
Tel.: +39 051 6144004 - Fax: +39 051 6142772
E-mail: stefania.parolari@iec-srl.it

Thursday, December 1st, 2016 – Afternoon
Salone del Podestà - Palazzo Re Enzo

Opening ceremony

18.00 **Welcome addresses**
C. Borghi (Bologna, I)

18.15 ***Main Lecture***

Introduction: **M. H. Alderman** (New York, NY - USA)
E. Ambrosioni (Bologna, I)

Uric acid and CV and metabolic disease: from the back to the future
R. J. Johnson (Denver, CO-USA)

19.00 Welcome cocktail

Friday, December 2nd 2016 – Morning
Salone del Podestà - Palazzo Re Enzo

Session I – Serum Uric Acid and Gout: from the human evolution to mechanism of disease

Chairpersons: **I. Olivieri (Potenza, I)**
F. Perez Ruiz (Vizcaya, E)

- 09.00 **F. M. Galassi** (Zurich, CH)
Uric acid and CV disease: an historical perspective
- 09.30 **T. Gibson** (London, UK)
Biochemistry of Uric Acid in clinical perspective
- 10.00 **E. E. Kelley** (Morgantown, WV-USA)
Which XOR-Derived product is driving the metabolic/cardiovascular dysfunction allied to obesity/diabetes, ROS or uric acid?
- 10.30 **H. Sakurai** (Tokyo, J)
Transporter-centric view of urate (patho)physiology
- 11.00 *Coffee break*

Session II – Serum uric acid, gout and cardio-renal disease: the genetic approach

Chairpersons: **J. Dawson** (Glasgow, UK)
M. Volpe (Rome, I)

- 11.30 **T. Merriman** (New Zealand)
Genetic aspects of gout
- 12.00 **J. Dawson** (Glasgow, UK)
Genes, uric acid and CV diseases
- 12.30 **C. Zoccali** (Reggio Calabria)
The challenge of Mendelian randomization approach
- 13.00 *Lunch*

Friday, December 2nd 2016 – Afternoon
Salone del Podestà - Palazzo Re Enzo

Session III – Gout and cardio-renal co-morbidities

Chairpersons: **P. Pauletto** (Treviso, I)
G. Minisola (Rome, I)

- 14.00 **L. Punzi** (Padua, I)
The interaction between gout and other rheumatic diseases: current trends
- 14.30 **C. Ferri** (L'Aquila, I)
The problem of cardio-renal diseases in patients with gout
- 15.00 **F. Perez Ruiz** (Vizcaya, E)
The management of gout in the era of complexity
- 15.30 *Coffee break*

Session IV – Serum uric acid and hypertension

Chairpersons: **G. Mancia** (Milan, I)
A. Manolis (Athens, GR)

- 16.00 **D. I. Feig** (Birmingham, AL, USA)
Uric acid and hypertensive disease at early age.
- 16.30 **G. Grassi** (Milan, I)
Effects of serum uric acid on blood pressure lowering treatment
- 17.00 **S. Taddei** (Pisa, I)
The effect of antihypertensive drugs on serum uric acid: does it matter?
- 17.30 **Main Lecture**
Introduction: **M. H. Alderman** (New York, NY - USA)
A. Lerman (Rochester, MN - USA)
Serum Uric Acid and the endothelium: is this the battlefield?
- 18.00 End of the session

Saturday, December 3rd 2016 – Morning
Salone del Podestà - Palazzo Re Enzo

Session V – Uric acid and cardiovascular diseases beyond hypertension

Chairpersons: **L. Ruilope** (Madrid, E)
P.G. Camici (Milano, I)

- 08.30 **L. O. Lerman** (Rochester, MN - USA)
Hyperuricemia and CV disease: the role of renal impairment
- 09.00 **W. Döhner** (Berlin, D)
Complexity of heart failure: the emerging role of hyperuricemia
- 09.30 **A. J. Manolis** (Athens, GR)
Serum uric acid and atrial fibrillation: update on epidemiology and disease mechanism
- 10.00 **C. Borghi** (Bologna, I)
Hyperuricemia and new onset diabetes/metabolic syndrome
- 10.30 *Coffee break*

Session VI – Open issues in the management of hyperuricemia

Chairpersons: **E. Agabiti-Rosei** (Brescia, I)
A. Stack (Limerick, IRL)

- 11.00 **G. Desideri** (L'Aquila, I)
Is there any “J-shaped” curve for serum uric acid?
- 11.30 **Y. Shibagaki** (Tokyo, J)
Renal protective effects of urate lowering drugs
- 12.00 **R. Pontremoli** (Genoa, I)
Does urate lowering treatment reduces CV risk in renal patients?
- 12.30 **T. MacDonald** (Dundee, UK)
Cardiovascular effects of urate lowering treatment: the role of drugs
- 13.00 **J. T. Kielstein** (Braunschweig, D)
The preventive role of urate lowering treatment: who should be treated?
- 13.30 Concluding Remarks
- 13.45 *Lunch*

GENERAL INFORMATION

Meeting venue

The venue for the Meeting will be **Salone del Podestà, Palazzo Re Enzo** – Piazza del Nettuno, 1 - Bologna

Secretariat during the Meeting

The Secretariat will be open at the following times:

Thursday, December 1st, from 05.00 p.m. to 07.00 p.m.

Friday, December 2nd, from 08.00 a.m. to 06.00 p.m.

Saturday, December 3rd, from 08.00 a.m. to 01.30 p.m.

Official language

The official language of the Meeting will be English.

Registration

The Meeting is free to attend.

Please confirm the participation to the Organizing Secretariat **within Friday, November 4th, 2016.**

Technical facilities

Facilities will be available for computer presentations and overhead projections.

A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentation to the business center at least one hour before the session starts.

The slide center will be open at the following times:

Thursday, December 1st, from 05.00 p.m. to 07.00 p.m.

Friday, December 2nd, from 08.00 a.m. to 06.00 p.m.

Saturday, December 3rd, from 08.00 a.m. to 01.30 p.m.

Lunches and coffee breaks

Lunches and coffee breaks will be served in the Meeting area.

Abstracts book

Participants will receive the Abstract book at the Meeting.

Certificate of attendance

The certificate of attendance will be available, on request, at the end of the Meeting at the Secretariat.

Italian CME Credits

Italian credits for Italian Physicians have been requested for **December 2nd – 3rd only.**

Provider Italian CME Credits:

I&C srl PROVIDER: 5387

ID CME ITALIAN CREDITS: 5387- 168136

CME CREDITS N. 5,5

I&C srl is responsible for the content, the quality and the ethical honesty of the CME activity.

The meeting is accredited for the following specialties:

Nurse, Pharmacist, Biologist, Physician and Surgeon (Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene).

The physicians belonging to other disciplines will not get the credits.

The attendance to the meeting is partially on sponsor companies invitation.

METHODOLOGY

Residential

COURSE OBJECTIVES

Clinical, Diagnostic, Therapy, Treatment Path

LEARNING TEST

The credits will be obtained by attending both days of the meeting (100% of attendance), by answering correctly to the 75% of the CME test questions and by filling the CME forms delivered at the meeting.

European CME Credits

EBAC and EACCME credits have been requested for **December 1st - 2nd - 3rd** for the following disciplines: Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene.



'URIC ACID CARDIOVASCULAR DISEASE: BACK TO PATHOPHYSIOLOGY' (Event code: 14792) was granted **10 European CME credits** (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

'URIC ACID CARDIOVASCULAR DISEASE: BACK TO PATHOPHYSIOLOGY' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

'URIC ACID CARDIOVASCULAR DISEASE: BACK TO PATHOPHYSIOLOGY' is designated for a maximum of (or 'for up to') 10 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.



European Board for Accreditation in Cardiology

The event "URIC ACID CARDIOVASCULAR DISEASE: BACK TO PATHOPHYSIOLOGY" is accredited by the European Board for Accreditation in Cardiology (EBAC) for **12 CME** credit hours of External CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

LIST OF SPEAKERS, CHAIRPERSONS AND CO-PRESIDENTS OF THE MEETING

Enrico AGABITI-ROSEI

Department of Clinical and Experimental Sciences
University of Brescia
Spedali Civili di Brescia
Brescia (Italy)

Michael H. ALDERMAN

Distinguished University Professor Emeritus
Departments of Medicine and Population Health
Albert Einstein College of Medicine
Bronx, New York NY (USA)

Ettore AMBROSIONI

Italian Society of Hypertension
Bologna (Italy)

Claudio BORGHI

Department of Medical and Surgical Sciences (DIMEC)
Alma Mater Studiorum University of Bologna
Bologna (Italy)

Paolo Guido CAMICI

Myocardial Diseases Center
San Raffaele Hospital
Milan (Italy)

Jesse DAWSON

Institute of Cardiovascular & Medical Sciences
University of Glasgow, Queen Elizabeth University Hospital
Glasgow (United Kingdom)

Giovambattista DESIDERI

UOC Geriatrics and Long-term care
Medical Department ORM
University of L'Aquila
L'Aquila (Italy)

Wolfram DOEHNER

Centre for Stroke Research
University of Berlin
Berlin (Germany)

Daniel I. FEIG

Department of Pediatrics
Division of Nephrology
University of Alabama
Birmingham and Children's of Alabama
Birmingham AL (USA)

Claudio FERRI

Division of Internal Medicine and Nephrology
School of Internal Medicine
University of L'Aquila
San Salvatore Hospital
Coppito - L'Aquila (Italy)

Francesco M. GALASSI

Institute of Evolutionary Medicine
Faculty of Medicine
University of Zurich
Zurich (Switzerland)

Terence GIBSON

Department Acute Medicine
St Thomas Hospital
London (United Kingdom)

Guido GRASSI

Department of Health Sciences
University of Milano-Bicocca
Milan (Italy)

Richard J. JOHNSON

Division of Renal Diseases and Hypertension
University of Colorado
Anschutz Medical Campus
Denver CO (USA)

Eric E. KELLEY

Department of Physiology and Pharmacology
West Virginia University
School of Medicine
Morgantown, WV (USA)

Jan T. KIELSTEIN

Medical Clinic V - Nephrology and Hypertension
Academic Teaching Hospital Braunschweig
Braunschweig (Germany)

Amir LERMAN

Division of Nephrology and Hypertension
Mayo College of Medicine
Rochester MN (USA)

Lilach O. LERMAN

Division of Nephrology and Hypertension
Mayo College of Medicine
Rochester MN (USA)

Thomas MACDONALD
School of Medicine
University of Dundee
Dundee (United Kingdom)

Giuseppe MANCIA
Department of Health Sciences
University of Milano-Bicocca
Milan (Italy)

Athanasios J. MANOLIS
Department of Cardiology
Hospital of Asklepeion
Athens (Greece)

Tony R. MERRIMAN
Biochemistry Department
School of Medical Sciences
University of Otago
Dunedin (New Zealand)

Giovanni MINISOLA
Rheumatology Unit
San Camillo Hospital
Rome (Italy)

Ignazio B. OLIVIERI
Rheumatology Department of Lucania
San Carlo Hospital of Potenza and
Madonna delle Grazie Hospital of Matera (Italy)

Paolo PAULETTO
Department of General Medicine
Ca' Foncello Hospital
Treviso (Italy)

Fernando PEREZ RUIZ
Rheumatology Division
Cruces University Hospital
Vizcaya (Spain)

Roberto PONTREMOLI
Department of Internal Medicine and Medical Specialties
University of Genova
Genoa (Italy)

Leonardo PUNZI
Rheumatology Unit
Department of Medicine
Medical School
University of Padua
Padua (Italy)

Luis Miguel RUILOPE

Hypertension Unit
Hospital 12 de Octubre
Madrid (Spain)

Hiroyuki SAKURAI

Department of Pharmacology and Toxicology
School of Medicine
Kyorin University
Tokyo (Japan)

Yugo SHIBAGAKI

Department of Internal Medicine
Division of Nephrology and Hypertension, Dept. of Internal Medicine
St Marianna University School of Medicine
Kanagawa (Japan)

Austin STACK

Department of Nephrology
University Hospital Limerick
Limerick (Ireland)

Stefano TADDEI

Department of Internal Medicine
University of Pisa
Pisa (Italy)

Massimo VOLPE

Cardiology Unit
Department of Cardiothoracic and Vascular Science
Faculty of Medicine and Psychology
Sapienza University of Roma
Rome (Italy)

Carmine ZOCCALI

CNR-IFC
Clinical Epidemiology of Renal Diseases and Hypertension
Reggio Calabria (Italy)